Final INTRIGUE trial data highlight outcomes of ripretinib vs sunitinib in patients with GIST.
Gastrointestinal Stromal Tumors
Advertisement
Long-term results support the durable efficacy of binimetinib plus imatinib in treatment-naïve advanced GIST.
Researchers define characteristics of e-GISTS and determine whether endoscopic resection is a treatment option for patients.
Factors including young age and low preoperative PNI were linked to an unfavorable prognosis in high-risk patients with GIST.
A recent retrospective analysis sought to identify novel actionable alterations in patients with SDH-deficient GISTs.
Dr. Weinberg provides a recap of all of the GI oncology data of practice-changing potential presented at ESMO 2024.
Little is known about the details of genomic differences and clinical implications between patients with GISTs.
Researchers specifically used data from the SEER-22 and SEER-17 registries.
The AI model used predictors of recurrence and duration imatinib treatment to determine recurrence risk.
A higher density of CD8+ T cells was linked to a more favorable PFS, but only to a limited extent.
Without surgical pathological confirmation, it is difficult to determine the risk level of GISTs in affected patients.
![Utilizing [68Ga]-NeoBOMB1 for Wild Type GIST](https://mumcdnstorage.blob.core.windows.net/gionc/2025/03/GIST-2.0.png)
NeoBOMB1 can be used in the theranostic setting for wtGIST when no effective standard of care treatment is available.
Part 1 of the Peak study shows an “encouraging” safety profile for bezuclastinib plus sunitinib in patients with GISTs.
Rectal gastrointestinal stromal tumors are rare, making up only 0.1% of all rectal neoplasms and about 5.0% of all GISTs.
A study compared the long-term survival outcomes of endoscopic and surgical treatment for GISTs ranging from 5 to 10 cm.
Patients diagnosed with GISTs can face a higher risk of additional malignancies, including genitourinary cancers.
Ripretinib has previously been identified as an effective inhibitor of secondary KIT mutations while in the AL.
Patients with moderate- or high-risk GIST receive adjuvant imatinib therapy following surgical resection.
While imatinib is considered standard-of-care, there is a lack of clinical data for the treatment among elderly patients.
Surgical treatment combined with targeted therapy may improve OS and CSS in patients with GIST-SLM.
A final overall survival and updated safety analysis from the phase 3 INTRIGUE study.
Topline results from the pivotal phase III INVICTUS trial showed that the novel drug ripretinib improved ...
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.